In the evolving landscape of biotechnology, mRNA process development has gained significant prominence, especially in the realm of in vitro transcription (IVT). High yield and integrity are fundamental quality indicators in IVT processes. High yield is essential for cost-effectiveness, while high integrity ensures product quality. T7 RNA Polymerase, a pivotal enzyme in IVT, is crucial for mRNA quality. Hzymes, leveraging five core technology platforms, offers comprehensive solutions for mRNA synthesis. This article delves into various aspects of mRNA process development, focusing on enhancing yield and integrity through innovative approaches and case studies.

The Importance of High Yield and Integrity in IVT

High Yield and Cost-Effectiveness

Achieving high yield in IVT is crucial for reducing production costs. The efficiency of the IVT process directly impacts the amount of mRNA produced, which in turn affects the scalability and economic viability of mRNA-based therapeutics. High yield means more product from the same amount of raw materials, making the process more cost-effective.

Integrity and Product Quality

The integrity of mRNA is vital for ensuring the effectiveness and safety of mRNA-based products. High integrity mRNA has fewer truncations and modifications, leading to better performance in therapeutic applications. It ensures that the mRNA can be translated accurately into the desired protein, maintaining the efficacy of the treatment.

Role of T7 RNA Polymerase in IVT

T7 RNA Polymerase is a key enzyme in the IVT process. It catalyzes the synthesis of RNA from a DNA template. The quality and performance of this enzyme directly influence the yield and integrity of the mRNA produced. Hzymes has developed advanced T7 RNA Polymerase mutants to enhance the IVT process.

Hzymes’ Five Core Technology Platforms

Hzymes employs five core technology platforms to optimize mRNA process development:

1.Enzyme Gene Resource Exploration: Identifying and utilizing the best genetic resources for enzyme production.
2.Directed Evolution of Enzyme: Enhancing enzyme performance through iterative cycles of mutation and selection.
3.Enzyme Artificial Intelligence Design: Using AI to design enzymes with improved characteristics.
4.Large-Scale Enzyme Manufacturing: Scaling up enzyme production to meet industrial demands.
5.Enzyme Catalytic System Application: Applying optimized enzymes in various catalytic processes for better outcomes.

Case Studies in IVT Process Optimization

Case 1: Enhancing Yield and Integrity

In this case, Hzymes utilized the T7 RNA Polymerase mutant (HBP000330) and a buffer library to assist clients in optimizing the IVT reaction. This approach significantly improved both the yield and integrity of the mRNA produced. The tailored buffer conditions and enhanced enzyme performance ensured that the process was both efficient and produced high-quality mRNA.

Case 2: Reducing dsRNA Content

Double-stranded RNA (dsRNA) is an unwanted byproduct in IVT processes as it can induce immune responses. Hzymes addressed this issue by using the T7 RNA Polymerase low dsRNA mutant (HBP000340) and the high-temperature-resistant mutant (HBP000350). These mutants helped in optimizing the IVT reaction to minimize dsRNA content, resulting in a purer final product.

Case 3: Producing Ultra-Short Fragments

Producing ultra-short mRNA fragments (below 300 nt) with high purity is challenging. Hzymes employed the T7 RNA Polymerase mutant variant (HBP000330) and a specialized buffer library to develop an IVT reaction capable of producing these short fragments. This process not only achieved the desired fragment length but also maintained high purity.

Case 4: Producing Ultra-Long Fragments

Producing ultra-long mRNA fragments with high integrity is equally challenging. By utilizing the T7 RNA Polymerase mutant (HBP000330) and the buffer library, Hzymes optimized the IVT reaction to produce ultra-long fragments. This process ensured that the mRNA fragments were of high integrity, suitable for various therapeutic applications.

LNP Process Development Services

Importance of LNP in mRNA Delivery

Lipid nanoparticles (LNPs) are critical for delivering mRNA molecules into cells. A well-designed delivery system protects mRNA from degradation, ensures efficient delivery to target sites, facilitates cell membrane passage, and releases mRNA within cells. Hzymes adopts mainstream LNP delivery systems for this purpose.

Preparation of mRNA-LNP Encapsulation

The preparation of mRNA-LNP encapsulation involves formulating lipid components and controlling the interaction between mRNA and lipids. Hzymes employs microfluidics mixing technology, where mRNA and liposome solutions are mixed under high pressure, creating stable, uniform mRNA-LNP complexes. The process includes:

– Mixing mRNA and liposome solutions: Achieved through opposing jets under high pressure, causing strong turbulence for thorough mixing.
– Precipitation of liposomes: Occurs as the ethanol phase is diluted and the pH changes, forming lipid nanoparticles.

Purification Post-Encapsulation

Post-encapsulation, it’s crucial to purify the mRNA-LNP complexes. This involves removing unencapsulated mRNA, free polymers, and lipid materials, and adjusting the concentration and pH. Tangential flow filtration (TFF) is used for this purpose. For example, after encapsulating 4000nt mRNA, TFF with a hollow fiber column is used to dilute, filter, and concentrate the mRNA-LNP complexes.


In Vivo Expression of mRNA-LNP

Delivering firefly luciferase mRNA-LNP into mice demonstrated successful in situ expression, targeting the liver and spleen. This validates the effectiveness of Hzymes’ mRNA-LNP encapsulation process.

Purification Process Development

Importance of Purification in mRNA Production

Purification is critical in mRNA production to ensure the safety and effectiveness of the final product. Impurities can affect mRNA translation efficiency and alter immunogenicity. Removing impurities such as residual substrates, dsRNA, abnormal mRNA, DNA templates, and protease residues is essential.

Hzymes’ mRNA Downstream Purification Process

Hzymes’ downstream purification process includes several key steps to ensure high-quality mRNA production:

1.UF/DF Filtration: Ultrafiltration/diafiltration (UF/DF) is the first step, where IVT reaction products are filtered to remove impurities like RNA polymerase, DNA templates, NTPs, and enzymes. The product is concentrated and exchanged into a buffer solution.
2.Oligo dT or Multimodal Chromatography: This step captures mRNA by hybridizing with the polyA tail using oligo dT resin or by separating contaminants using multimodal chromatography. This removes impurities lacking the polyA tail, such as free nucleotides and short chain transcripts.
3.Second UF/DF Filtration: Further concentration and buffer exchange are performed to place the product into the final formulation buffer.
4.Sterilization and Filtration: The final step involves sterilizing the product by filtering it through a 0.2 µm filter and filling it into sterile containers.

Special Considerations

Components that cannot be confirmed as nuclease-free should be treated with 0.5M NaOH for at least one hour, then washed with nuclease-free water and the appropriate buffer.

Case Data: Purification Process for 4000nt mRNA

For 4000nt mRNA, Hzymes’ purification process involves several steps to ensure high purity and yield. After IVT, the mRNA undergoes UF/DF filtration to remove large impurities and exchange the buffer. Next, oligo dT resin is used to capture mRNA, removing contaminants lacking the polyA tail. A second UF/DF filtration further concentrates the product and exchanges it into the final buffer. Finally, sterilization and filtration ensure the product is free from any remaining impurities.

Conclusion

The development of mRNA processes, from IVT to purification and encapsulation, involves a series of complex and highly specialized steps. High yield and integrity are critical for the economic viability and quality of mRNA products. Hzymes’ advanced T7 RNA Polymerase mutants and comprehensive purification processes ensure that mRNA products meet the highest standards of quality and efficacy. By leveraging cutting-edge technologies and innovative approaches, Hzymes continues to lead the way in mRNA process development, paving the way for more effective and accessible mRNA-based therapeutics.

In the future, Hzymes biotech will always remember its original intention and persist in meticulous cultivation in the IVD field. It will adhere to independent research and development, accelerate the construction of a world-class specialty enzyme production platform, and achieve import substitution of core enzyme raw materials in the field of biomedicine in China. It will collaborate with leading biopharmaceutical companies to expand their global presence and contribute to the advancement of the industry.